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Aims: Treatment with glucagon-like peptide (GLP)-1 receptor agonists or dipeptidyl peptidase
(DPP)-4 inhibitors might increase gallstone formation; however, the mechanisms involved are
unknown. We aimed to assess the effects of these drugs on gallbladder volume and bile acid
proﬁle.
Materials and methods: A total of 57 type 2 diabetes patients (mean  SD age, 62.8  6.9
years; BMI, 31.8  4.1 kg/m2; HbA1c, 7.3%  0.6%), treated with metformin and/or sulfony-
lureas, were included in this 12-week randomized, placebo-controlled, double-blind, single-
centre trial between July 2013 and August 2015 at the VU University Medical Center, the
Netherlands. Patients received the GLP-1 receptor agonist liraglutide, the DPP-4 inhibitor sita-
gliptin or matching placebo for 12 weeks. Gallbladder fasting volume and ejection fraction were
measured using ultrasonography after a high-fat meal. Serum bile acids were measured in the
fasting and postprandial state and in faecal samples. The trial was registered at ClinicalTrials.
gov (NCT01744236).
Results: Neither liraglutide nor sitagliptin had an effect on gallbladder fasting volume and ejec-
tion fraction (p > .05). Liraglutide increased serum levels of deoxycholic acid in the fasting state
[0.20 μmol/L (95% CI 0.027-0.376), p = 0.024] and postprandial state [AUC 40.71 (13.22-
68.21), p = 0.005] and in faeces [ratio 1.5 (1.03-2.19); p = 0.035]. Sitagliptin had no effect on
serum bile acids, but increased faecal levels of chenodeoxycholic acid [ratio 3.42 (1.33-8.79),
p = 0.012], cholic acid [ratio 3.32 (1.26-8.87), p = 0.017] and ursodeoxycholic acid [ratio 3.81
(1.44-10.14), p = 0.008].
Conclusions: Neither liraglutide nor sitagliptin has an effect on gallbladder volume. Observed
changes in bile acids with liraglutide suggest alterations in the intestinal microbiome, while sita-
gliptin appears to increase hepatic bile acid production.
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1 | INTRODUCTION
Since 2005 glucagon-like peptide (GLP)-1 based therapies, i.e. GLP-1
receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors, have
been established treatment options in the management of type 2 dia-
betes. These drug classes exploit the insulinotropic and glucagono-
static effects of GLP-1, thereby effectively lowering blood glucose.1
In addition, GLP-1 (receptor agonists) inhibits gastric emptying, gas-
tric acid secretion and other aspects of proximal gastrointestinal
physiology.1 Interestingly, recent studies also suggest a role of GLP-
1-based therapies in biliary physiology. Acute administration of the
GLP-1 receptor agonist exenatide markedly reduced cholecystokinin-
stimulated gallbladder emptying by ~40% in healthy volunteers.2
Moreover, serum bile acid levels are reduced in DPP-4 deﬁcient mice,
compared to wild type mice, which is explained by a reduction in bile
acid production and enhanced bile acid excretion.3 Finally, in rat hep-
atocyte cultures, both GLP-1 peptide and exenatide reduce CYP7A1,
the hepatic cytochrome which converts cholesterol to bile acids.3
The effects of GLP-1 based therapies on gallbladder emptying
and bile acid production could explain several observations. First,
these actions may accelerate gallstone-formation and explain reports
of cholelithiasis and cholecystitis with the use of these agents.4–7 In
two recent large randomized clinical trials, liraglutide increased the
risk of cholelithiasis by > 50%.4,7 Moreover, reduced bile acid con-
centration in the small intestine decreases lipid digestion and absorp-
tion, which could contribute to the beneﬁcial effects of GLP-1-based
therapies on postprandial lipid proﬁles. Since bile acids are also
important regulators of glucose homeostasis,8 a reduction in bile acid
secretion could also have negative glycaemic effects.
The effects of GLP-1-based therapies on gallbladder motility and
bile acid physiology have not been studied during prolonged treat-
ment or in patients with type 2 diabetes. Therefore, we examined our
hypothesis that the GLP-1 receptor agonist liraglutide and the DPP-4
inhibitor sitagliptin inhibit gallbladder emptying and reduce bile acid
production in patients with type 2 diabetes.
2 | MATERIALS AND METHODS
This was a randomized, placebo-controlled, double-blind, parallel-group
study in which patients received 12-week treatment with liraglutide
(Novo Nordisk A/S, Bagsvaerd, Denmark), sitagliptin (Merck & Co,
Kenilworth, NJ, USA) or matching placebos. The full protocol has been
published previously.9 The study was performed at the VU University
Medical Center (VUmc), the Netherlands between July 2013 and
August 2015 and was approved by the ethics review board of the
VUmc. It is registered at clinicaltrials.gov (NCT01744236) and was con-
ducted in accordance with the Declaration of Helsinki and the Interna-
tional Conference on Harmonisation of Good Clinical Practice. All
participants provided written informed consent before participation.
2.1 | Participants
We recruited 60 Caucasian patients with type 2 diabetes using news-
paper advertisements. Patients were males or postmenopausal
females (35-75 years of age; BMI, 25-40 kg/m2) and had an HbA1c
of 6.5%-9.0% (48-75 mmol/mol). They were treated with a stable
dose of metformin and/or sulfonylurea derivatives for at least
3 months. Relevant exclusion criteria were: current treatment with
insulin or GLP-1-based therapy; cholecystectomy; history of hepatic,
pancreatic, cardiovascular or renal disease; an estimated glomerular
ﬁltration rate < 60 mL/min/1.73 m2; allergy to any of the test sub-
stances; alcohol intake > 3 units/d.
2.2 | Treatment and randomization
Eligible patients were randomly assigned to receive liraglutide 1.8 mg,
sitagliptin 100 mg or placebo (1:1:1 allocation ratio; block size of six).
Randomization was performed by the trial pharmacist using
computer-generated numbers, allowing patients and trial physicians
to remain blinded to study-group assignments. Because of the differ-
ent administration routes of liraglutide (subcutaneous) and sitagliptin
(oral), all subjects received pens for subcutaneous injections and oral
capsules, ﬁlled with active drug or placebo. Preﬁlled pens with either
liraglutide or placebo were provided by Novo Nordisk, while sitaglip-
tin and placebo were encapsulated by ACE Pharmaceuticals
(Zeewolde, the Netherlands). Study drugs were taken once daily, at
the same time of day in the evening. Subcutaneous injections were
started at a dose of 0.6 mg for the ﬁrst week, 1.2 mg for the second
week and 1.8 mg for the remaining 10 weeks. Based on tolerance to
the study drug, the time between dose increments could be extended
and the dose could be reduced.
2.3 | Study end points and procedures
Endpoint measurements were performed at baseline (after a run-in
period of 4 weeks to ensure stable conditions) and after 12-week
treatment. As previously described,9 all biliary measurements were
secondary endpoints. Gallbladder emptying was measured using
meal-stimulated ultrasonography. Bile acid physiology was assessed
by fasting and by postprandial serum bile acids and faecal bile acids.
Additionally, gastric emptying was measured using the acetamino-
phen absorption test,10 to allow correction for the possible inﬂuence
of gastric emptying on biliary physiology.
Gallbladder ultrasonography, the acetaminophen absorption test
and measurement of the serum bile acid proﬁle were performed dur-
ing a single visit before and after 12-week treatment. Moreover,
patients were asked to bring a stool sample, as described below.
Before each visit, patients were instructed to refrain from using alco-
hol or nicotine for at least 12 hours. Patients were instructed to
arrive at the clinical research unit of the Diabetes Center VUmc in
the fasting state, delaying all morning medication apart from metfor-
min. An intravenous catheter was placed in an antecubital vein on
the left arm, after which participants assumed a supine position dur-
ing the entire visit. Gallbladder volume was measured and blood sam-
ples were taken. Then, a high-fat mixed meal was given, which
consisted of two slices of whole-wheat bread with 20 g of butter and
250 mL of semi-skimmed milk (total of 22.4 g fat), after which the
tests were repeated.
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2.3.1 | Gallbladder ultrasonography
Gallbladder volume was measured at 15-minute intervals, starting
before the meal and continuing 180 minutes after the meal. Sono-
graphic gallbladder images were obtained using a 3.5 MHz Siemens
4C1 curved abdominal transducer on a Sequoia Acuson ultrasound
device (Siemens Healthcare GmbH, Erlangen, Germany). The maximal
length, width and height of the gallbladder were obtained and
recorded from longitudinal and axial cross-sectional images. Per time
moment, measurements were performed in triplicate, and the largest
diameters were used for calculations. Gallbladder volume was calcu-
lated using the volume of an ellipsoid: 0.52 × length (cm) × width
(cm) × height (cm).11 The smallest postprandial gallbladder volume
was termed the residual volume (RV). The ejection fraction (EF) was
calculated for each postprandial time point using the formula: (fasting
volume – volume at corresponding time point)/fasting volume × 100.
The maximum EF was calculated as: (fasting volume – RV)/fasting vol-
ume × 100.12,13 Finally, the area under the curve (AUC) of gallbladder
volume was calculated.
2.3.2 | Serum bile acids
Levels of unconjugated and tauro- and glycine-conjungated bile acids
– chenodeoxycholic acid (CDCA), tauro-CDCA (TCDCA), glycine-
CDCA (GCDCA), cholic acid (CA), tauro-GCA (TCA), glycine-CA
(GCA), deoxycholic acid (DCA), tauro-DCA (TDCA), glycine-DCA
(GDCA), litocholic acid (LCA), tauro-LCA (TLCA), glycine-LCA (GLCA),
ursodeoxcycholic acid (UDCA), tauro-UDCA (TUDCA) and glycine-
UDCA (GUDCA) – were measured in serum samples drawn from
intravenous catheters before meal ingestion, and 30, 60 and
120 minutes thereafter. The bile acid proﬁle was assessed as
described previously.14 In short, serum samples were puriﬁed by cen-
trifugation, evaporation and ﬁltration. Then, quantitative determina-
tion of bile acids was performed using a Nexera X2 Ultra High
Performance Liquid Chromatography system (Shimadzu, Kyoto,
Japan), coupled to a Sciex QTRAP 4500 MD triple quadrupole mass
spectrometer (Sciex, Framingham, MA, USA) (UHPLC-MS/MS). Bile
acids were separated with an Acquity UPLC BEH C18 Column
equipped with an Acquity UPLC BEH C18 VanGuard Pre-Column
(Waters, Milford, MA, USA). The peak area was calculated for each
serum sample and related to the peak area of an internal standard
(D4-labeled bile acids). Bile acid levels below the detection limit of
0.05 μM were classiﬁed as 0.025 μM. For statistical analyses, the
AUC and incremental AUC (iAUC) were calculated using the trape-
zoid rule. Moreover, the sum of primary (CA and CDCA) and second-
ary (DCA, LCA, UDCA) bile acids and the sum of conjugated and
unconjugated bile acids were calculated.
2.3.3 | Faecal bile acids and neutral sterols
Levels of unconjugated bile acids (CDCA, CA, DCA, LCA and iso-LCA)
and neutral sterols (cholesterol, dihydrocholesterol and coprostanol)
were measured in stool samples, using sample tubes with a scoop in
the screw-top. Patients were carefully instructed on collection techni-
ques (to avoid contamination), storage in a dark and cool place and
transport to the clinical research unit. Within two days of collection,
samples were frozen at −80C. Bile acids and neutral sterols were
analysed as described previously.15 After lyophilization and homoge-
nization of faeces, bile acids and neutral sterols were determined by
capillary gas chromatography on an Agilent gas chromatograph
(HP 6890), equipped with a 25 m × 0.25 mm (0.2 μm stationary
phase) CP-Sil-19-fused silica column (Varian, Middelburg, the Nether-
lands) and a ﬂame ionisation detector. Bile acid levels below the
detection limit of 2 nmol were classiﬁed as 1 nmol.
2.3.4 | Gastric emptying
To measure gastric emptying, 1.5 g liquid acetaminophen (62.5 mL
Daro Paracetamol, Remark Groep, Rogat, the Netherlands) was added
to the mixed meal. Prior to the meal, and every 30 minutes following
the meal up to 180 minutes, serum was collected. After centrifugation,
serum was stored at −80C until analysis. Serum acetaminophen levels
were determined using an enzymatic immunoassay on an Architect
4000 (Abbott Laboratories, Abbott Park, IL, USA). The absolute area
under the curve (AUC) was calculated, and the maximal acetaminophen
concentration (Cmax) and the time to reach Cmax (Tmax) were noted.
2.3.5 | Laboratory measurements
Venous blood glucose was measured in all blood samples using an
YSI-2300 STAT Glucose analyser (YSI Life Sciences, Yellow Springs,
OH, USA). HbA1c, triglycerides, cholesterol, high-density lipoprotein
cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C)
were assayed by conventional methods at the Department of Clinical
Chemistry in our hospital.16
2.4 | Sample size, data management and
statistical analysis
As current data are part of a larger study,9 of which the biliary effects
were included as secondary endpoints, no a-priori power calculation was
performed. However, when using numbers from the study in healthy
subjects,2 where acute exenatide administration reduced ejection frac-
tion (36.5%, SD ~15%), we calculated that 14 participants per group
would be sufﬁcient (parallel-group design, α 0.05, power (1 − β) 80%).
All data were double-entered into an electronic data manage-
ment system (OpenClinica LLC, version 3.3, Waltham, MA, USA) and
exported to the study database. To test treatment effects versus pla-
cebo, multivariable regression models were used on the per-protocol
population. Treatment with liraglutide or sitagliptin was added as a
dummy-variable, while baseline variables of the tested endpoint were
included as covariate to correct for baseline differences between the
treatment arms. Results of these tests are presented as treatment-
induced effect with 95% CI, corrected for baseline values. Because
faecal bile acids demonstrated a non-Gaussian distribution, log-
transformation was applied before analysis, and the anti-log back
transformation of the results is shown. Correlations between
treatment-induced changes in bile acids, weight and metabolic para-
meters were measured using the Pearson correlation technique.
Because metformin is known to alter bile acid metabolism,17 addi-
tional sub-analyses were performed, where a daily dose of metformin
was added to the regression models as covariate. No corrections for
multiple testing were performed, to decrease the risk of false-negative
ﬁndings in this hypothesis-generating study. All analyses were
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performed using SPSS 22.0 (IBM SPSS Inc., Chicago, IL, USA), and a
two-sided p-value < 0.05 was considered statistically signiﬁcant.
3 | RESULTS
3.1 | Study population
After inclusion but before randomization, two patients withdrew
informed consent and two patients were excluded because of inciden-
tal ﬁndings (malignancy). Thus, 56 patients were randomized to liraglu-
tide (n = 19), sitagliptin (n = 20) or placebo (n = 17) (Figure S1,
Supporting Information). Treatment was well tolerated, with adverse
effects in equal numbers among treatment groups, apart from gastro-
intestinal disturbances (nausea, diarrhoea; present in 12 liraglutide-
treated patients, in two sitagliptin-treated patients and in none of the
placebo-treated patients). In the sitagliptin-group, one patient with-
drew from the trial because of dizziness and pollakisuria. Per-protocol
baseline characteristics were similar among the three groups (Table 1).
3.2 | Gallbladder emptying
Neither treatment inﬂuenced fasting volume, RV, maximal EF or the
AUC of gallbladder volume, compared with placebo (p > .05) (Figure 1).
3.3 | Serum bile acids
Liraglutide increased fasting serum levels of DCA compared with pla-
cebo [0.20 μmol/L (95% CI 0.027-0.376), p = .024] (Figure 2). Moreo-
ver, the postprandial AUC of DCA increased with liraglutide
[40.71 μmol/l/2 h (95% CI 13.22-68.21), p = .005). Other serum indi-
vidual bile acids, total bile acids, total conjugated and unconjugated
bile acids and total tauro- and glycine-conjugated bile acids were not
different between treatment groups (p > .05).
3.4 | Faecal bile acids
Compared with placebo, both liraglutide [ratio 1.36 (95% CI 0.97-
1.91), p = .071] and sitagliptin [ratio 1.36 (95% CI 0.97-1.91),
p = .077] tended to increase faecal total bile acids. Liraglutide
increased DCA [ratio 1.5 (95% CI 1.03-2.19); p = .035], without
affecting other bile acids (Figure 3). Sitagliptin increased CDCA [ratio
3.42 (95% CI 1.33-8.79), p = .012] and CA [ratio 3.32 (95% CI 1.26-
8.87), p = .017]. Moreover, sitagliptin increased UDCA levels [ratio
3.81 (95% CI 1.44-10.14), p = .008]. Neither therapy affected the
amount of faecal neutral sterols or total sterols (p > .05).
3.5 | Additional effects
Liraglutide or sitagliptin did not change acetaminophen Cmax, Tmax or
AUC, compared to placebo (Figure S2, Supporting Information). No
effects of liraglutide or sitagliptin were observed on fasting triglycer-
ides, total cholesterol, HDL-C and LDL-C levels. Liraglutide tended to
reduce weight by 1.7 kg (95% CI −3.6-0.3; p = .09), while body
weight was stable with sitagliptin [−0.8 (−2.7 to 1.0); p = .374]. Lira-
glutide decreased HbA1c by 1.3% (−1.7 to −0.9; p < .001) or
14.1 mmol/mol (−18.7 to −9.4), while sitagliptin lowered HbA1c by
0.8% (−1.4 to −0.4; p = .001) or 8.6 mmol/mol (−13.4 to −3.8). Both
liraglutide and sitagliptin reduced fasting glucose [1.5 mmol/L (−2.3
to −0.8), p < .001 and 0.9 mmol/L (−1.7 to −0.2), p = .015, respec-
tively] and postprandial glucose AUC [390.9 (−569.6 to −212.4),
p < .001 and 230.2 (−416.7 to −43.8), p = .017, respectively] of glu-
cose, compared with placebo. After exclusion of two outliers (placebo
n = 1, sitagliptin n = 1), the change in the AUC of DCA and glucose
was signiﬁcantly correlated (R −0.353, p = .011; Figure S3, Support-
ing Information). No other statistically signiﬁcant correlations
between changes in faecal CA, CDCA, DCA and UDCA, serum DCA,
and weight, HbA1c, and fasting and postprandial glucose were
observed. Finally, correction for the use of metformin did not yield
different results (data not shown).
4 | DISCUSSION
In the current study we observed no effects of 12-week treatment
with liraglutide or sitagliptin on gallbladder emptying. Liraglutide
increased both plasma and faecal levels of the secondary bile acid
TABLE 1 Subject baseline characteristics
Parameter Sitagliptin (n = 19) Liraglutide (n = 19) Placebo (n = 17)
Age (years) 61.7  6.8 60.5  7.2 65.8  5.8
Male sex [n (%)] 16 (84.2%) 14 (73.7%) 13 (76.5%)
Weight (kg) 99.4  17.6 105.9  17.2 95.8  9.8
BMI (kg/m2) 31.5  4.3 33.3  4.5 30.6  2.9
FPG (mmol/L) 8.0  0.9 8.3  1.4 8.9  2.0
HbA1c (%) 7.1  0.5 7.4  0.7 7.5  0.7
HbA1c (mmol/mol) 53.8  5.6 57.1  7.3 58.2  7.9
Duration of T2D (years) 8.1  5.8 7.7  4.5 8.2  4.8
Metformin use [n (%)] 18 (94.7%) 19 (100%) 15 (88.2%)
Sulfonylurea use [n (%)] 9 (47.4%) 7 (36.8%) 8 (47.1%)
Systolic BP (mm Hg) 132.5  12.4 136.6  17.0 137.6  14.9
Diastolic BP (mm Hg) 75.2  7.4 76.9  5.4 76.4  6.8
Data are presented as means  SD for continuous data, and number (percent of total) for count data. No statistically signiﬁcant between-group differ-
ences were observed using ANOVA and Chi-square tests. BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; T2D, type 2 diabetes.
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DCA. Sitagliptin increased faecal excretion of the primary bile acids
CA and CDCA, and the secondary bile acid UDCA, without affecting
fasting or postprandial serum bile acid levels.
We observed no effect on gallbladder emptying with a GLP-1
receptor agonist or DPP-4 inhibitor. This ﬁnding contrasts with a pre-
vious study by Keller et al., where acute administration of exenatide
strongly reduced gallbladder emptying in healthy volunteers.2 This
discrepancy can be explained by several factors. First, gallbladder
emptying was triggered directly by CCK-infusion in that study, while
we used high-fat meal stimulation. Consequently, other (intestinal)
factors activated by meal-ingestion could have inﬂuenced the effect
of GLP-1 based therapies in the current real-life situation. Second,
patients with type 2 diabetes frequently have reduced gallbladder
emptying compared with healthy volunteers (~50% vs. ~75%, respec-
tively).18 Potentially, a lower baseline emptying rate prevents a signif-
icant effect of an intervention. Finally, as is clearly established for the
effects of GLP-1 receptor agonists on gastric emptying rate, tachy-
phylaxis may occur with long-acting (e.g. liraglutide), but not with
short-acting (e.g. exenatide) agents.1 The lack of effect of liraglutide
on gastric emptying in the current study underlines this hypothesis.
The DPP-4 inhibitor sitagliptin had no effect on gallbladder emptying,
which is in line with the current paradigm that these agents have little
to no effect on proximal gastro-intestinal motility.19
The effects of liraglutide and sitagliptin on bile acids differed.
Physiologically, the liver produces the primary bile acids CDCA and
CA, while the intestinal microbiome converts these into the second-
ary bile acids DCA, UDCA and LCA. Liraglutide increased the second-
ary bile acid DCA in serum and faeces. Because DCA originates by
microbial 7-dehydroxylation of the primary bile acid CA, in the
absence of other changes in bile acid proﬁle, the most probable
explanation of this liraglutide-induced increase in DCA levels is an
alteration in intestinal microbiota. The excess of DCA is both
excreted in faeces and absorbed as part of the enterohepatic circula-
tion. While these data suggest changes in microbiota, effects of GLP-
1-based therapies on the intestinal microbiome remain unstudied.
Sitagliptin signiﬁcantly increased faecal levels of CA, CDCA and
UDCA, and a similar pattern was seen with DCA and (iso-)LCA. Inter-
estingly, serum levels of these bile acids also increased, although this
did not reach statistical signiﬁcance. In the steady state, faecal bile
acid secretion is a direct measure of body bile acid synthesis. Because
bile acids are produced only in the liver, the increase in faecal bile
acids indicates augmentation of hepatic bile acid production. In a
recent study by Nunez et al., sitagliptin had no effect on serum bile
acid levels and C4-levels as proxy for bile acid synthesis in 13 patients
with type 2 diabetes.20 Faecal bile acid excretion was not reported
by Nunez et al., precluding a direct comparison of their data with
those of the present study.
Several reports have suggested that both GLP-1 receptor agonists
and DPP-4 inhibitors may increase the development of
cholelithiasis.4–7 In general, any factor that contributes to impaired gall-
bladder function, bile cholesterol supersaturation or precipitation might
cause gallstone formation. Our data suggest that changes in gallbladder
emptying are not involved in the pathophysiology of cholelithiasis with
GLP-1-based therapies. However, although we did not measure biliary
bile acid levels, the liraglutide-induced increase in serum and faecal
DCA levels leads to the speculation of increased biliary levels, which is
(A) (B)
(C) (D)
FIGURE 1 Gallbladder emptying. Gallbladder volume as measured using ultrasonography; A, before intervention and B, after 12-week
treatment with placebo, sitagliptin or liraglutide. Measurements were performed in the fasting state and after a high-fat mixed meal; C, maximal
ejection fraction (EF) at baseline and after 12-week treatment; D, area under the curve of the gallbladder volume at baseline and after 12-week
treatment. No signiﬁcant effects were observed.
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(A) (B) (C)
(D) (E) (F)
(G) (H) (I)
(J) (K) (L)
(M)
FIGURE 2 Bile acids in serum. Area under the curve (AUC) and incremental-AUC (iAUC) for the postprandial serum bile acids before and after 12-
week treatment with placebo (PCB), sitagliptin (SITA) or liraglutide (LIRA). Data are presented as μmol/l/2 h. A, cholic acid (CA); B, taurocholic acid
(TCA); C, glycocholic acid (GCA); D, chenodeoxycholic acid (CDCA); E, tauro chenodeoxycholic acid (TCDCA); F, glycochenodeoxycholic acid
(GCDCA); G, deoxycholic acid (DCA); H, taurodeoxycholic acid (TDCA); I, glycodeoxycholic acid (GDCA); J, ursodeoxycholic acid (UDCA); K, glyco-
ursodeoxycholic acid (GUDCA); L, litocholic acid (LCA); and M, glycinelitocholic acid (GLCA). Tauro-ursodeoxycholic acid (TUDCA) and
taurolithocholic acid (TLCA) are not depicted, as most values were below the detection limit. All data are presented as mean with standard error of
the mean. Asterisks (*) indicate statistically signiﬁcant differences (p < .05) between treatment and placebo, corrected for baseline differences.
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a known inducer of cholesterol hypersecretion and gall stone forma-
tion.21 Since DCA did not increase during sitagliptin-treatment, other
(indirect) factors may be involved. Weight loss and dietary alterations
are well-recognized risk factors for gallstone development. However,
while these occur during GLP-1 receptor agonist treatment, they are
not present during DPP-4 inhibitor treatment, and as such, are proba-
bly not involved. Finally, a direct drug-induced increase in biliary cho-
lesterol excretion could be involved, similar to drug-classes like
ﬁbrates.22 While in hepatocytes of DPP-4 deﬁcient mice an increase in
mRNA of the cholesterol-transporter (ABCG8) is found,3 suggestive of
increased biliary cholesterol excretion, we found no differences in fae-
cal cholesterol or neutral sterol levels between treatment groups.
From a metabolic perspective, increased levels of bile acids could
be relevant. Accumulating data suggest that bile acids improve
metabolism through activation of the farnesoid X receptor (FXR) and
G protein-coupled bile acid receptor 1 (or TGR5).16 FXR stimulation
reduces hepatic gluconeogenesis and improves insulin sensitivity,
while TGR5 activation increases energy expenditure and insulin sensi-
tivity. However, most of these data stem from animal studies, and
the only clinical study with a TGR5 agonist found no consistent effect
on metabolic parameters.23 Nevertheless, since liraglutide treatment
reduces hepatic gluconeogenesis and improves insulin sensitivity and
energy expenditure,24,25 it would be of interest to study whether bile
acids may have mediated some of these effects. Although our study
was not designed to speciﬁcally test this hypothesis, we did observe
an inverse correlation between the postprandial DCA-curve and post-
prandial glucose-curve.
An increase in bile acids could induce adverse effects. For exam-
ple, an excess of faecal bile acids could induce bile acid diarrhoea.
Diarrhoea occurs frequently with liraglutide, yet is not a common side
effect of sitagliptin.26 Mechanisms underlying the drug-associated
diarrhoea have not been studied, although some suggest that an
osmotic factor is involved.27 However, since DCA has the highest
potency to cause bile acid diarrhoea,28 this could explain the discrep-
ancy between liraglutide and sitagliptin. Increased faecal bile acid
concentration could also increase the risk of colon carcinoma, as
especially DCA has been implicated in tumorigenesis.29 However, no
signal for colon carcinoma has arisen from large clinical trials to date.
Metformin reduces serum bile acids and increases the intestinal
bile acid pool, probably by reduction of ileal bile acid reuptake.30
Although metformin use was stable in the current study, evenly dis-
tributed across the groups, and did not affect the effects of the GLP-
1-based therapies on bile acid composition, an interaction between
the various drugs cannot be excluded. Unfortunately, we were not
(A) (B) (C)
(D) (E) (F)
(G) (H) (I)
FIGURE 3 Bile acids in faeces. Faecal bile acids and neutral sterols after 12-weeks of treatment with placebo (PCB), sitagliptin (SITA) or
liraglutide (LIRA). A, cholic acid (CA); B, chenodeoxycholic acid (CDCA); C, deoxycholic acid (DCA); D, ursodeoxycholic acid (UDCA); E, lithocholic
acid (LCA); F, iso-lithocholic acid (iso-LCA); G, coprostanol; H, cholesterol; and I, dihydrocholesterol. All data are presented as median with
interquartile range (box) and total range (whiskers). A logarithmic scale was chosen for the y-axis because of the wide range of values. Asterisks
(*) indicate statistically signiﬁcant differences (p < .05) between treatment and placebo, corrected for baseline differences.
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able to test this hypothesis, since only three patients were not using
metformin, which ﬁts daily clinical practice.
This study has some limitations that need to be recognized. First,
for practical reasons, we did not use gold standard tests for gallblad-
der and gastric emptying (scintigraphy) or bile acid physiology (iso-
tope-measured kinetics). Second, since no active comparator was
used, the effects of liraglutide and sitagliptin through glucose lower-
ing cannot be excluded. However, the current trial aimed to assess
real-life effects of GLP-1-based therapies, disregarding whether these
effects are caused by or beyond glucose lowering. Third, we did not
measure the pharmacokinetics of liraglutide or (over-encapsulated)
sitagliptin in this study. For the latter, capsules were used which fully
degrade within 10 minutes of ingestion, without affecting the phar-
macokinetics of the included tablets itself. Fourth, although none of
the collected faecal samples were watery diarrhoea, we did not col-
lect data on precise stool consistency and stool frequency, which
could theoretically have inﬂuenced the results of the faecal tests.
Finally, although the study was adequately powered to assess the
hypothesis, the groups were not ﬁt for speciﬁc subgroup analyses.
To conclude, while liraglutide and sitagliptin have no effect on
gallbladder emptying, both agents increase levels of bile acids,
although differentially. The increase in faecal and serum bile acids
during liraglutide treatment suggests alteration of intestinal micro-
biome, while sitagliptin appears to increase hepatic bile acid
production.
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